SSP
CAI

Sixth Street Partners’s Caris Life Sciences CAI Stock Holding History

Sixth Street Partners’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131M Sell
7,327,041
-7,058,358
-49% -$126M 22.54% 2
2026
Q1 		$257M Sell
14,385,399
-5,000,000
-26% -$109M 36.19% 1
2025
Q4 		$523M Sell
19,385,399
-5,000,000
-21% -$141M 53.72% 1
2025
Q3 		$738M Hold
24,385,399
– – 63.36% 1
2025
Q2 		$652M Buy
+24,385,399
New +$657M 51.71% 1

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sixth Street Partners's CAI Position: Q2 2026 in Review

Sixth Street Partners reduced its Caris Life Sciences (CAI) stake by 49% in Q2 2026, selling an estimated $126M and leaving 7,327,041 shares worth $131M. The position accounts for 22.54% of the portfolio, ranked #2.

Sixth Street Partners first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $738M in Q3 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Sixth Street Partners held 7,327,041 shares of Caris Life Sciences worth $131M as of Q2 2026.
  • Sixth Street Partners sold 7,058,358 Caris Life Sciences shares in Q2 2026, an estimated $126M.
  • Caris Life Sciences made up 22.54% of Sixth Street Partners's portfolio in Q2 2026, its #2 holding.
  • Sixth Street Partners first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • Sixth Street Partners's Caris Life Sciences position peaked at $738M in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Sixth Street Partners's 13F filing for Q2 2026, filed 14 Aug 2026.